eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2023
vol. 25
 
Share:
Send email
Share:
Original paper

The effect of a combination of motivational counselling with armodafinil therapy in obese patients with shift work disorder in primary care

Victoria Tkachenko
1
,
Taisiia Bagro
1, 2

  1. Department of Therapy, Family Medicine, Hematology and Transfusion, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
  2. Municipal non-commercial enterprise of the Kyiv Regional Council “Kyiv Regional Clinical Hospital”, Kyiv, Ukraine
Family Medicine & Primary Care Review 2023; 25(4): 436–441
DOI: https://doi.org/10.5114/fmpcr.2023.132617
Online publish date: 2023/12/27
Article file
- 09 FM&PCR 4 23 - O - Tkachenko - 1360 - The effect.pdf  [0.46 MB]
Get citation
 
PlumX metrics:
 
1. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ 2020; 192(31): 875–891, doi: 10.1503/cmaj.191707.
2. Nastanova 00500. Obesity treatment guideline DUODECIM MedicalPublications, Ltd. 2017 [cited 30.03.2023]. Available from URL: https://guidelines.moz.gov.ua/documents/3336.
3. Obesity Canada published First Update to 2020 Adult Clinical Practice Guidelines: press release. 2022 Oct 21 [cited 30.03.2023]. Available from URL: https://obesitycanada.ca/.
4. North American Association for the Study of Obesity National Heart Lung and Blood Institute National Institutes of Health (U.S.) NHLBI Obesity Education Initiative. The Practical Guide: Identification Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda Md: National Institutes of Health National Heart Lung and Blood Institute NHLBI Obesity Education Initiative North American Association for the Study of Obesity [serial online]. 2000 Oct [cited 30.03.2023]. Available from URL: https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf.
5. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts 2016; 9(1): 642015, doi: 10.1159/000442721.
6. Mayer SB, Graybill S, Raffa SD, et al. Synopsis of the 2020 U.S. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity. Mil Med 2021; 186(9–10): 884–896, doi: 10.1093/milmed/usab114.
7. Obesity: identification, assessment and management Clinical guideline [CG189]. Published: 27 November 2014. [serial online] 2022 September 08 [cited 30.03.2023]. Available from URL: https://www.nice.org.uk/guidance/cg189/chapter/Recommendations#pharmacological-interventions.
8. Call for authors – Special issue: Interventions for the treatment of persons with obesity Deadline of submission [serial online] 17 June 2022 [cited 30.03.2023]. Available from URL: https://www.who.int/news-room/articles-detail/call-for-authors-special-issue-interventions-for-the-treatment-of-persons-with-obesity.
9. Sobczak K, Leoniuk K. Attitude towards obesity and its treatment – analysis of the attitudes of patients with obesit. Fam Med Prim Care Rev 2020; 22(4): 325–330, doi: 10.5114/fmpcr.2020.100443.
10. Weight Loss Agents. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases [serial online] 2020 June [cited 30.03.2023]. Avail-able from URL: https://pubmed.ncbi.nlm.nih.gov/31644235/.
11. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2011; 36(6): 843–854, doi: 10.1038/ijo.2011.158.
12. Raatz S, Gross AC. Clinical Assessment and Treatment of Early-Onset Severe Obesity. Curr Obes Rep 2021; 10(1): 31–38, doi: 10.1007/s13679-020-00418-6.
13. National clinical evidence based guideline «Obesity in adults» [serial online] 2023 March [cited 30.03.2023]. Available from URL: https://www.dec.gov.ua/mtd/ozhyrinnya-u-doroslyh/.
14. Website of FDA. Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm
15. Pedersen SD, Manjoo P, Wharton S. Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy for Obesity Management. Adult Obesity Clinical Practice Guidelines are a living document, with only the latest chapters posted at obesitycanada.ca/guidelines. Update History Version 2 [serial online] 2022 October 21 [cited 30.03.2023]. Avail-able from URL: https://obesitycanada.ca/guidelines/pharmacotherapy.
16. Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet 2016; 387(10031): 1947–1956, doi: 10.1016/S0140-6736(16)00271-3.
17. Gadde KM, Martin CK, Berthoud HR, et al. Obesity: Pathophysiology and Management. J Am Coll Cardiol 2018; 71(1): 69–84, doi: 10.1016/j.jacc.2017.11.011.
18. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352(9123): 167–172, doi: 10.1016/s0140-6736(97)11509-4.
19. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20(3): 270–279, doi: 10.1592/phco.20.4.270.34882.
20. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL – Primary Health Care Trial. Diabetes Obes Metab 2005; 7(1): 21–27, doi: 10.1111/j.1463-1326.2004.00428.x.
21. Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2012; 7(6): e39062, doi: 10.1371/journal.pone.0039062.
22. Tkachenko V, Bagro T. Quality of life, mental health and sleep disorders in obese people of working age. West Kazakhstan Medical Journal 2021; 63(3): 152–157, doi: 10.24412/2707-6180-2021-63-145-151.
23. Chapman JL, Cayanan EA, Hoyos CM, et al. Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial. Am J Respir Crit Care Med 2018; 198(7): 941–950, doi: 10.1164/rccm.201712-2439OC.
24. Auger RR, Burgess HJ, Emens JS, et al. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2015; 11(10): 1199–1236, doi: 10.5664/jcsm.5100.
25. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39(3): 281–288.
26. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39(1): 30–40, doi: 10.1177/00912709922007534.
27. Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002; 68(1): 107–112, doi: 10.1002/jnr.10196.
28. Mitchell HA, Bogenpohl JW, Liles LC, et al. Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action. Pharmacol Biochem Behav 2008; 91(2): 217–222, doi: 10.1016/j.pbb.2008.07.014.
29. Qu WM, Huang ZL, Xu XH, et al. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008; 28(34): 8462–8469, doi: 10.1523/JNEUROSCI.1819-08.2008.
30. Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009; 29(2): 87–100, doi: 10.2165/0044011-200929020-00003.
31. Food and Drug Administration. FDA-approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets. [serial online] 2007 June 15. Available from URL: http://www.accessdata.fda.gov.
32. Beck P, Odle A, Wallace-Huitt T, et al. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008; 31(12): 1647–1654, doi: 10.1093/sleep/31.12.1647.
33. Darwish M, Kirby M, Hellriegel ET, et al. Armodafinil and modafinil have substantially different pharmacokinetic pro-files despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009; 29(9): 613–623, doi: 10.2165/11315280-000000000-00000.
34. Ministry of Health Protection of Ukraine. Pharmaceutical Management State Expert Center of the Ministry of Health of Ukraine. State Register of Medicinal Products of Ukraine. Available from URL: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlz1?opendocument&stype = 7AB171087377F824C22586D30038838B.
35. Mavanji V, Pomonis B, Kotz CM. Orexin, serotonin, and energy balance. WIREs Mech Dis 2022; 14(1): e1536, doi: 10.1002/wsbm.1536.
36. D’Ettorre G, Pellicani V, Caroli A, et al. Shift work sleep disorder and job stress in shift nurses: implications for preventive interventions. Med Lav 2020; 111(3): 195–202, doi: 10.23749/mdl.v111i3.9197.
37. Lallukka T, Kaikkonen R, Härkänen T, et al. Sleep and sickness absence: a nationally representative register-based follow-up study. Sleep 2014; 37: 1413–1425, doi: 10.5665/sleep.3986.
38. Veghari G, Sedaghat M, Joshghani H, et al. Obesity and risk of hypercholesterolemia in Iranian northern adults. ARYA Atheroscler 2013; 9(1): 2–6.
39. Corica F, Corsonello A, Apolone G, et al. Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients. Obesity 2006; 14(8): 1429–1437, doi: 10.1038/oby.2006.162.
40. Lee W, Kwon C, Rhee E, et al. The effect of body mass index and fasting glucose on the relationship between blood pressure and incident diabetes mellitus: a 5-year follow-up study. Hypertens Res 34(2011): 1093–1097, doi: https://doi.org/10.1038/hr.2011.89.
41. Galen KA, van, Ter Horst KW, Serlie MJ, et al. Serotonin, food intake, and obesity. Obes Rev 2021; 22(7): e13210, doi: 10.1111/obr.13210.
42. Howard R, Roth T, Drakeet CL. The effects of armodafinil on objective sleepiness and performance in a shift work dis-order sample unselected for objective sleepiness. J Clin Psychopharmacol 2014; 34(3): 369–373, doi: 10.1097/JCP.0000000000000136.
43. Tkachenko V, Bagro T. Mental health and sleep disorders in obese patients, their relationship with clinical-pathogenetic changes in the body and impact on quality of life. Fam Med Eur Pract 2020; 4(102): 5–10, doi: 10.30841/2786-720X.4.2022.274617.
44. Tkachenko V, Bagro T. Effectiveness of motivational counseling for lifestyle modification in obese patients using a patient-centered approach. Fam Med Eur Pract 2023; 1(103): 20–27, doi: 10.30841/2786-720X.1.2023.277475.
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.